Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

4imprint hails 'resilient' performance ahead of AGM

(Sharecast News) - 4imprint Group said on Wednesday that it delivered a "resilient" operational and financial performance in the early part of 2025, against a backdrop of volatile macroeconomic conditions. In an update ahead of its annual meeting, the direct marketer of promotional products said group revenue in the first four months of the year was in line with the same period a year earlier.

4imprint said order intake has continued to run about 2% below the prior year, while average order values were even. It said gross margins have remained "strong" and the marketing mix has provided the flexibility and efficiency it expected.

"Although the recently announced temporary reduction of tariffs on US imports from China moderates their impact in the near term, we expect an element of supply chain disruption and higher product costs during the second half of the year," the company said.

"In addition, any impact the situation surrounding tariff policy may have on the broader macro-economic backdrop is difficult to predict. However, as demonstrated in previous periods of uncertainty and supply chain disruption, the group's strategy, including a strong balance sheet, gives the business a competitive advantage."

4imprint said it remains confident in its ability to navigate the current uncertain environment, "delivering the best possible near-term financial results while positioning the business to take advantage of opportunities that will present themselves as certainty returns".

Results for the 26 weeks to 28 June 2025 are due on 6 August.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.